ADHD and Appetite Suppression
ADHD and Appetite Suppression: Understanding the Effects of Stimulant Medications
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most frequently diagnosed neurodevelopmental conditions in children and adolescents. Central nervous system (CNS) stimulants such as methylphenidate, amphetamines, and lisdexamfetamine remain the cornerstone of ADHD treatment due to their proven effectiveness in improving attention, impulse control, and hyperactivity. Yet, one of the most commonly reported concerns among parents and clinicians is appetite suppression and its potential impact on growth.
This article explores how stimulant medications influence appetite, body weight, and growth across different populations, what recent research says about long-term risks, and how clinicians are managing these effects in special populations—such as children with co-occurring eating disorders.
How Stimulants Affect Appetite
CNS stimulants like methylphenidate and amphetamines increase dopamine and norepinephrine activity in the brain. These neurotransmitters enhance alertness and focus but also influence appetite regulation within the hypothalamus. As a result, children and adolescents often experience decreased hunger, particularly during daytime hours when medications are active.
These appetite changes can translate to modest reductions in caloric intake and slower weight gain over time. As documented in The Side Effects of Drugs Annual series, stimulants, which include lisdexamfetamine, methylphenidate, and modafinil, as well as appetite suppressants such as phentermine, have a well-documented anorectic effect (Scarpa, Kshatriya & Bello, 2021; Akgun, Uzumcu & Bello, 2024). Appetite loss tends to be most pronounced in the early months of treatment and may diminish as the body adjusts.
Evidence from Long-Term Studies
Concerns about growth suppression have led researchers to closely monitor height, weight, and BMI in children treated for ADHD over several years. Zachor et al. (2006) studied 89 children treated with psychostimulants over three years and found significant initial weight loss, especially in children with appetite suppression or those who were heavier at baseline. However, body mass index (BMI) remained within normal limits, and there was no clinically significant long-term effect on height.
Similarly, large-scale meta-analyses and follow-up studies confirm that the effects of stimulants on growth tend to be modest and self-limiting. A systematic review by Charach et al. (2021) found that methylphenidate use was associated with slight but statistically significant reductions in height and weight Z-scores, though the differences were unlikely to have long-term clinical implications. Growth parameters often normalize after several years or when medication is discontinued.
Another review by Waxmonsky et al. (2021) emphasized that while stimulants can slow growth velocity, particularly during the first two years of continuous use, eventual catch-up growth frequently occurs. Moreover, limiting lifetime stimulant exposure or taking “drug holidays” during weekends or summers can significantly mitigate these effects.
Managing Appetite Suppression in Clinical Practice
Clinicians approach appetite suppression using several strategies:
Monitoring Growth: Regular measurement of height and weight, often every three to six months, ensures that potential effects are detected early. Most guidelines recommend using standardized growth charts to track changes over time.
Optimizing Dosage and Timing: Adjusting the timing of medication or prescribing lower doses can help shift peak appetite suppression away from mealtime.
Nutritional Interventions: Encouraging high-calorie breakfasts before medication onset and nutrient-dense snacks in the evening when appetite returns.
Medication Switches or Augmentation: In select cases, non-stimulant medications such as atomoxetine may substitute for or complement stimulants when appetite effects are problematic.
ADHD, Stimulants, and Eating Disorders
A newer and particularly complex challenge involves treating children and adolescents diagnosed with both ADHD and avoidant/restrictive food intake disorder (ARFID)—a condition marked by limited eating and potential malnutrition. Since appetite suppression is a known side effect of stimulant medication, clinicians have questioned whether continuing stimulants could worsen ARFID symptoms or hinder weight restoration.
However, emerging case series from specialized eating disorder treatment programs suggest otherwise. Finn et al. (2023) reported that continued stimulant use, combined with structured behavioral support, allowed children with comorbid ADHD and ARFID to maintain concentration and gradually restore weight. In these cases, stimulant therapy helped with emotional regulation and engagement in treatment when paired with mealtime structure and contingency management plans. Some patients benefited from augmenting stimulant therapy with mirtazapine, an antidepressant known to improve appetite and reduce nausea.
These findings challenge the traditional assumption that stimulant therapy must be paused in the presence of an eating disorder. Instead, evidence suggests that, under supervision, stimulants can be safely maintained within structured care settings, enabling children to treat both ADHD and restrictive eating behaviors simultaneously.
The Balancing Act: Benefits vs. Side Effects
Overall, the consensus across studies is reassuring. While stimulant medications do suppress appetite and can temporarily slow growth, these side effects are generally mild, reversible, and outweighed by the cognitive and behavioral benefits of ADHD symptom control. Each child responds differently, so individualized care—balancing effective ADHD management with close nutritional and growth monitoring—is key.
As highlighted by recent Side Effects of Drugs Annual reviews, continued vigilance and newer research remain
References
Akgun, E. E., Uzumcu, M., & Bello, N. T. (2024). Central nervous system stimulants and drugs that suppress appetite. In Side Effects of Drugs Annual (Vol. 46, pp. 547–561). Elsevier.
Charach, A., et al. (2021). Long term methylphenidate exposure and growth in children and adolescents with ADHD: A systematic review and meta-analysis.Neuroscience & Biobehavioral Reviews, 120, 509–525. sciencedirect.com
Finn, D. M., Menzel, J. E., Gray, E., & Schwartz, T. (2023). Pharmacotherapy for ADHD in youth with avoidant restrictive food intake disorder: A case series.Journal of Eating Disorders, 11(1), 226.
Scarpa, L. L., Kshatriya, D., & Bello, N. T. (2021). Central nervous system stimulants and drugs that suppress appetite. In Side Effects of Drugs Annual (Vol. 43, pp. 1–15). Elsevier.
Waxmonsky, J. G., Baweja, R., & Hale, D. E. (2021). Impact of CNS stimulants for ADHD on growth.CNS Drugs, 35(8), 839–859. link.springer.com
Zachor, D. A., Roberts, A. W., Hodgens, J. B., Isaacs, J. S., & Merrick, J. (2006). Effects of long-term psychostimulant medication on growth of children with ADHD.Research in Developmental Disabilities, 27(2), 162–174.